Welcome to the Kublin Lab. We study the role of the microbiome in vaccine responses, and focus on how specific microbes and their metabolites modulate host innate and adaptive immune responses. Our work includes developing discrete microbial consortia to manipulate vaccine responses in gnotobiotic mouse models, as well as investigating microbiome and immunogenicity data from HIV, malaria, and TB clinical trials.
Utilizing gnotobiotic models to inform the role of the microbiome in vaccine response heterogeneity. Cram JA, Hager KW, Kublin JG.
A randomized trial of the prophylactic activity of DSM265 against pre-erythrocytic Plasmodium falciparum controlled human malaria infection by mosquito bites and direct venous inoculation. Murphy SC, Duke ER, Shipman KJ, Jensen RL, Fong Y, Ferguson S, Janes HE, Gillespie K, Seilie AM, Hanron AE, Rinn L, Fishbaugher M, VonGoedert T, Fritzen E, Kappe SH, Chang M, Sousa JC, Marcsisin SR, Chalon S, Duparc S, Kerr N, Möhrle JJ, Andenmatten N, Rueckle T, Kublin JG.
Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Kublin JG, Mikolajczak SA, Sack BK, Fishbaugher ME, Seilie A, Shelton L, VonGoedert T, Firat M, Magee S, Fritzen E, Betz W, Kain HS, Dankwa DA, Steel RW, Vaughan AM, Noah Sather D, Murphy SC, Kappe SH.
Hutch News | Sabin Russell | Nov. 22, 2017
We now know that microbial communities, especially in our guts, profoundly affect immune response.
Science Spotlight | BL DeBuysscher | Feb. 20, 2017
Researchers from the Kublin lab at Fred Hutch, UW and Seattle Biomedical Research Institutes are using genetic engineering to create a new genetically attenuated parasite (GAP) vaccine candidate.
Hutch News | Mary Engel | Jan. 4, 2017
New approach using genetically modified parasite ‘primes the immune system’ in first human trial.